 |
|
Administration of Recombinant Activated Factor VII in Major Thoracic Operations—Reply
Marco Ranucci, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
This response to our article addresses an interesting point. Prophylactic treatment with rFVIIa was found to be ineffective in some surgical settings, where major bleeding was not the rule. Of course, every randomized controlled trial (RCT) needs adequate power to detect significant differences between treatment and control groups. In this case, the outcome variables usually considered are (1) the allogeneic blood-product transfusion rate, (2) the amount of allogeneic blood products used, and (3) the amount of perioperative bleeding.
In their experience, Alavi and coworkers could not find any beneficial effect of rFVIIa in thoracic operations. To better address and comment on their findings, of course, it would be necessary to know the details of their RCT. Namely, it would be very important to know the preoperative profile of the patients and their historic transfusional needs and perioperative bleeding data. Moreover, we would need to know . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials
Marco Ranucci, Giuseppe Isgrò, Giorgio Soro, Daniela Conti, and Barbara De Toffol
Arch Surg. 2008;143(3):296-304.
ABSTRACT
| FULL TEXT
RELATED LETTER
Administration of Recombinant Activated Factor VII in Major Thoracic Operations
Ali-Asghar Alavi, Sayed Mahdi Jalali, Mohammad R. Rasouli, and Payam Eghtesadi-Araghi
Arch Surg. 2008;143(10):1021.
EXTRACT
| FULL TEXT
|
